阿司匹林预防慢性肾脏病患者动脉粥样硬化:ALTAS-CKD随机对照试验方案
ALTAS-CKD为多中心、前瞻性、随机、双盲、安慰剂对照试验,计划纳入554例中国3-5期非透析慢性肾脏病成人患者,随机接受阿司匹林100 mg每日一次或匹配安慰剂治疗36个月,主要终点为颈动脉超声评估的动脉粥样硬化发生,旨在明确抗血小板治疗在CKD患者中预防动脉粥样硬化的有效性与安全性。
要点
- CKD患者心血管疾病高发,但抗血小板药物用于CKD一级预防的获益与证据尚存争议。
- ALTAS-CKD纳入554例3-5期非透析CKD患者,随机接受阿司匹林100 mg每日一次或安慰剂治疗36个月。
- 主要终点为颈动脉超声评估的动脉粥样硬化发生,次要终点包括复合心血管事件、全因死亡和eGFR下降50%。
核心结论
- 该研究旨在确定抗血小板治疗能否在初级保健环境中安全预防CKD患者的动脉粥样硬化。
研究设计与样本
- ALTAS-CKD为多中心、前瞻性、随机、双盲、安慰剂对照试验。
- 计划从中国10个区域医疗中心招募554例3-5期非透析依赖的CKD成人患者。
- 采用安全网络计算机随机化系统,分配阿司匹林100 mg每日一次或匹配无活性安慰剂,治疗36个月。
关键数值与推荐
- 主要终点为颈动脉超声测量的动脉粥样硬化发生。
- 次要终点为复合心血管事件、全因死亡和估算肾小球滤过率下降50%。
- 试验注册号:ChiCTR1900021393,注册日期2019年2月18日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease (CVD) is the most common complication and the leading cause of death in patients with chronic kidney disease (CKD). Accelerated atherosclerosis is a pathophysiological process that is vital to the occurrence of cardiovascular complications associated with CKD. Abnormal platelet activation is not only the leading cause of atherosclerosis but also plays a critical role in the occurrence of thrombotic events. Currently, antiplatelet drugs are commonly used as a secondary prevention strategy for high blood pressure, obesity, diabetes, and ischemic heart disease and can reduce the risk of CVD in the susceptible population. However, the benefits and evidence of using antiplatelet agents in patients with CKD remain controversial. This study aimed to determine whether antiplatelet therapy can safely prevent atherosclerosis in patients with CKD in the primary care setting. METHODS/DESIGN: The ALTAS-CKD study is a multicenter, prospective, randomized, double-blind, placebo-controlled trial of 554 adult patients with stage 3-5 non-dialysis-dependent CKD recruited from 10 territory medical centers in China. A secured web-based computer randomization system will be used to administer aspirin 100 mg once daily or a matching inactive placebo for 36 months. The primary endpoint will be the occurrence of atherosclerosis, as measured by carotid ultrasonography. The secondary endpoints will be combined cardiovascular events, all-cause mortality, and 50% decrease in the estimated glomerular filtration rate. TRIAL REGISTRATION {2A}: Current controlled trials number: ChiCTR1900021393 . Registered on 18 February 2019.
引用
- Xiong J, He T, Yu Z, et al. Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients: study protocol for a randomized clinical trial. Trials. 2021. PMID: 33413594. doi:10.1186/s13063-020-04992-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。